{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:52:05Z","timestamp":1787939525423,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03189-5","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T07:33:38Z","timestamp":1746689618000},"page":"3173-3185","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United States"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9222-4479","authenticated-orcid":false,"given":"Nana","family":"Kragh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Worsfold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abiola","family":"Oladapo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elyse","family":"Swallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"10287","key":"3189_CR1","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/s0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(21)00569-9.","journal-title":"Lancet"},{"issue":"6","key":"3189_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007\u20132016. Arthritis Rheumat (Hoboken, NJ). 2019;71(6):991\u20139. https:\/\/doi.org\/10.1002\/art.40807.","journal-title":"Arthritis Rheumat (Hoboken, NJ)"},{"issue":"12","key":"3189_CR3","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/rheumatology\/kez196","volume":"58","author":"G Singh","year":"2019","unstructured":"Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. Rheumatology. 2019;58(12):2177\u201380. https:\/\/doi.org\/10.1093\/rheumatology\/kez196.","journal-title":"Rheumatology"},{"key":"3189_CR4","doi-asserted-by":"publisher","first-page":"e45943","DOI":"10.2196\/45943","volume":"9","author":"Q He","year":"2023","unstructured":"He Q, Mok TN, Sin TH, et al. Global, regional, and national prevalence of gout from 1990 to 2019: age-period-cohort analysis with future burden prediction. JMIR Public Health Surveill. 2023;9:e45943. https:\/\/doi.org\/10.2196\/45943.","journal-title":"JMIR Public Health Surveill"},{"key":"3189_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003025","author":"J Zhang","year":"2023","unstructured":"Zhang J, Jin C, Ma B, et al. Global, regional and national burdens of gout in the young population from 1990 to 2019: a population-based study. RMD Open. 2023. https:\/\/doi.org\/10.1136\/rmdopen-2023-003025.","journal-title":"RMD Open"},{"issue":"4","key":"3189_CR6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3899\/jrheum.170806","volume":"45","author":"MM Elfishawi","year":"2018","unstructured":"Elfishawi MM, Zleik N, Kvrgic Z, et al. The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol. 2018;45(4):574\u20139. https:\/\/doi.org\/10.3899\/jrheum.170806.","journal-title":"J Rheumatol"},{"issue":"2","key":"3189_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/BOR.0b013e3282f4eff5","volume":"20","author":"E Fels","year":"2008","unstructured":"Fels E, Sundy JS. Refractory gout: what is it and what to do about it? Curr Opin Rheumatol. 2008;20(2):198\u2013202. https:\/\/doi.org\/10.1097\/BOR.0b013e3282f4eff5.","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"3189_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s42358-023-00336-w","volume":"64","author":"Z Ji","year":"2024","unstructured":"Ji Z, Huang Y, Liang L, et al. Clinical characteristics and risk factors associated with bone erosion in patients with tophi. Adv Rheumatol. 2024;64(1):18. https:\/\/doi.org\/10.1186\/s42358-023-00336-w.","journal-title":"Adv Rheumatol"},{"issue":"6","key":"3189_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the management of gout. Arthritis Care Res. 2020;72(6):744\u201360. https:\/\/doi.org\/10.1002\/acr.24180.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"3189_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/00325481.2016.1113840","volume":"128","author":"P Khanna","year":"2016","unstructured":"Khanna P, Khanna D, Storgard C, Baumgartner S, Morlock R. A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. Postgrad Med. 2016;128(1):34\u201340. https:\/\/doi.org\/10.1080\/00325481.2016.1113840.","journal-title":"Postgrad Med"},{"issue":"10","key":"3189_CR11","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.3899\/jrheum.151199","volume":"43","author":"R Wood","year":"2016","unstructured":"Wood R, Fermer S, Ramachandran S, Baumgartner S, Morlock R. Patients with gout treated with conventional urate-lowering therapy: association with disease control, health-related quality of life, and work productivity. J Rheumatol. 2016;43(10):1897\u2013903. https:\/\/doi.org\/10.3899\/jrheum.151199.","journal-title":"J Rheumatol"},{"issue":"12","key":"3189_CR12","doi-asserted-by":"publisher","first-page":"e041167","DOI":"10.1136\/bmjopen-2020-041167","volume":"10","author":"SK Chen","year":"2020","unstructured":"Chen SK, Liu J, Kim SC. Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study. BMJ Open. 2020;10(12):e041167. https:\/\/doi.org\/10.1136\/bmjopen-2020-041167.","journal-title":"BMJ Open"},{"issue":"12","key":"3189_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/2042098617727714","volume":"8","author":"A Guttmann","year":"2017","unstructured":"Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment\u2014safety issues, latest evidence and clinical considerations. Ther Adv Drug Saf. 2017;8(12):379\u201388. https:\/\/doi.org\/10.1177\/2042098617727714.","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"3189_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2018.1532904","volume":"22","author":"NM Flores","year":"2019","unstructured":"Flores NM, Nuevo J, Klein AB, Baumgartner S, Morlock R. The economic burden of uncontrolled gout: how controlling gout reduces cost. J Med Econ. 2019;22(1):1\u20136. https:\/\/doi.org\/10.1080\/13696998.2018.1532904.","journal-title":"J Med Econ"},{"issue":"1","key":"3189_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40744-020-00260-1","volume":"8","author":"M Francis-Sedlak","year":"2021","unstructured":"Francis-Sedlak M, LaMoreaux B, Padnick-Silver L, Holt RJ, Bello AE. Characteristics, comorbidities, and potential consequences of uncontrolled gout: an insurance-claims database study. Rheumatol Ther. 2021;8(1):183\u201397. https:\/\/doi.org\/10.1007\/s40744-020-00260-1.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"3189_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.clinthera.2012.01.020","volume":"34","author":"H Park","year":"2012","unstructured":"Park H, Rascati KL, Prasla K, McBayne T. Evaluation of health care costs and utilization patterns for patients with gout. Clin Ther. 2012;34(3):640\u201352. https:\/\/doi.org\/10.1016\/j.clinthera.2012.01.020.","journal-title":"Clin Ther"},{"issue":"10","key":"3189_CR17","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s40273-015-0288-5","volume":"33","author":"GE Shields","year":"2015","unstructured":"Shields GE, Beard SM. A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics. 2015;33(10):1029\u201347. https:\/\/doi.org\/10.1007\/s40273-015-0288-5.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"3189_CR18","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/MJT.0b013e31820543c5","volume":"19","author":"EQ Wu","year":"2012","unstructured":"Wu EQ, Forsythe A, Gu\u00e9rin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy. Am J Ther. 2012;19(6):e157\u201366. https:\/\/doi.org\/10.1097\/MJT.0b013e31820543c5.","journal-title":"Am J Ther"},{"issue":"8","key":"3189_CR19","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2665-9913(24)00117-6","volume":"6","author":"M Cross","year":"2024","unstructured":"Cross M, Ong KL, Culbreth GT, et al. Global, regional, and national burden of gout, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2024;6(8):e507\u201317. https:\/\/doi.org\/10.1016\/S2665-9913(24)00117-6.","journal-title":"Lancet Rheumatol"},{"issue":"16","key":"3189_CR20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40265-023-01944-y","volume":"83","author":"R Terkeltaub","year":"2023","unstructured":"Terkeltaub R. Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review. Drugs. 2023;83(16):1501\u201321. https:\/\/doi.org\/10.1007\/s40265-023-01944-y.","journal-title":"Drugs"},{"issue":"5","key":"3189_CR21","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3899\/jrheum.080487","volume":"36","author":"EQ Wu","year":"2009","unstructured":"Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36(5):1032. https:\/\/doi.org\/10.3899\/jrheum.080487.","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"3189_CR22","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/annrheumdis-2017-eular.6023","volume":"76","author":"S Mitchell","year":"2017","unstructured":"Mitchell S, Manounah L, Liedgens H, Johannes E. AB0896 The effect of serum uric acid levels on tophus status and flares in patients with gout: a systematic review. Ann Rheumat Dis. 2017;76(Suppl 2):1369. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.6023.","journal-title":"Ann Rheumat Dis"},{"issue":"2","key":"3189_CR23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clinthera.2016.12.011","volume":"39","author":"RT Keenan","year":"2017","unstructured":"Keenan RT. Limitations of the current standards of care for treating gout and crystal deposition in the primary care setting: a review. Clin Ther. 2017;39(2):430\u201341. https:\/\/doi.org\/10.1016\/j.clinthera.2016.12.011.","journal-title":"Clin Ther"},{"key":"3189_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna PP, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117. https:\/\/doi.org\/10.1186\/1477-7525-10-117.","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"3189_CR25","doi-asserted-by":"publisher","first-page":"e007214","DOI":"10.1136\/bmjopen-2014-007214","volume":"5","author":"R Jackson","year":"2015","unstructured":"Jackson R, Shiozawa A, Buysman EK, Altan A, Korrer S, Choi H. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open. 2015;5(6):e007214. https:\/\/doi.org\/10.1136\/bmjopen-2014-007214.","journal-title":"BMJ Open"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03189-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03189-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:14:14Z","timestamp":1750493654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03189-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3189"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03189-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"6 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nana Kragh and Abiola Oladapo are employees of Sobi and may hold stock\/stock options in the company. Andew Worsfold was paid by Sobi to undertake various health economics and outcomes research services at the time of the study. Emily Gao, Sakshi Sethi, and Elyse Swallow are employees of Analysis Group, Inc., which provided paid consulting services to Sobi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is based on data from the IQVIA PharMetrics\u00ae Plus claims database. The database is de-identified and compliant with the Health Insurance Portability and Accountability Act of 1996 (HIPAA), therefore ethical review was not required. This article does not relate to any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}